Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
about
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.Gastric cancer prevention by demethylationCDKN2B, SLC19A3 and DLEC1 promoter methylation alterations in the bone marrow of patients with acute myeloid leukemia during chemotherapyTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesDecitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy aloneHypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway.Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors.D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
P2860
Q36545229-4EED37FC-B32A-444A-8657-8063213F230EQ36750927-EE80F573-A3F4-4C54-9243-72873D51DC8EQ36824910-F80A2B23-3E20-44E5-A170-31929B3EF65AQ37566878-8BDDB57F-26C5-4786-A053-12E8CA89F216Q37742267-36CF9FE3-FBFB-4866-9686-1AA9320D531BQ38838983-99F23A89-C683-438E-B3EF-BD2F8E388824Q38912946-3EA34DE7-B295-41FE-BAB4-F3A70E1296DCQ40055082-690D7518-9CFC-44B7-98AA-7A2A7406042BQ42112147-4DF1D2C0-BC40-4A72-A76D-DFE66F6943EEQ51594039-E616EA42-141F-4A5A-8121-4BB4F645E946Q53817619-3B545C6F-17FF-452B-9538-7185C1E93AFAQ57815598-D36D41BA-0DB9-487C-8D87-E29F8EB6C056
P2860
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Clinical outcome of treatment ...... actory acute myeloid leukemia.
@en
Clinical outcome of treatment ...... actory acute myeloid leukemia.
@nl
type
label
Clinical outcome of treatment ...... actory acute myeloid leukemia.
@en
Clinical outcome of treatment ...... actory acute myeloid leukemia.
@nl
prefLabel
Clinical outcome of treatment ...... actory acute myeloid leukemia.
@en
Clinical outcome of treatment ...... actory acute myeloid leukemia.
@nl
P2093
P2860
P1433
P1476
Clinical outcome of treatment ...... actory acute myeloid leukemia.
@en
P2093
Chun Kang Chang
Ling Yun Wu
Lu Xi Song
Qing Xia Zhang
P2860
P304
P356
10.1007/S00277-012-1550-Y
P577
2012-08-16T00:00:00Z